In this issue:
Enzalutamide vs AS for localised prostate cancer
Risk factors for clinically significant prostate cancer in PIRADS 3 lesions
ADT, docetaxel, and androgen receptor signalling inhibitors in mCSPC
Decipher genomic classifier for salvage radiotherapy
Focal cryoablation for intermediate- and high-risk prostate cancer
Functional and QoL outcomes of localised prostate cancer treatments
Patterns of failure following EBRT and additional focal boost
US- vs MRI-directed diagnostic pathways for suspected prostate cancer
3-D virtual reality models for RARP surgical planning
Multivitamin use and risk of overall and aggressive prostate cancer
Please login below to download this issue (PDF)